Press releases

2022-11-07 11:15 Lipum has initiated a Phase 1 clinical study with its drug candidate SOL-116
Lipum AB (publ) announces that the Phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. To date, a...
2022-10-19 17:00 Lipum announces outcome of directed share issue Regulatory
The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on the Directed Share Issue of 2,601,732...
2022-10-12 11:00 Lipum AB – Report from the Extraordinary General Meeting Regulatory
The EGM resolved to approve the Board of Directors’ previous resolution on September 22, 2022 on a directed share issue of 2,601,732 shares, whereby...
2022-09-27 14:45 Lipum gets approval to start Phase 1 clinical trial with drug candidate SOL-116
The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The...
2022-09-22 21:00 Lipum has resolved on a directed share issue of approximately SEK 39 million at a subscription price of SEK 14.99 per share Regulatory MAR
The Directed Share Issue comprises 2,601,732 new shares issued at a subscription price of SEK 14.99 per share, which means that the Company will raise...
2022-08-09 08:45 Lipum to participate in upcoming industry meetings
LSX Nordic, Copenhagen, Denmark, 6-7 September Biostock Investerarevent, digital, 14 September Nordic Life Science Days, Malmö, Sweden, 28-29 September...
2022-07-27 08:00 Lipum AB - interim report for the period January - June 2021 Regulatory
CEO Einar Pontén comments: “Through long-term and systematic work, we are now almost ready to start clinical trials. We have mitigated many...
2022-07-08 08:30 Lipum has recruited Helena Bergström as Chief Medical Officer
Dr. Helena Bergström is an experienced clinician that previously also has been involved in research of sex-and gender differences in medicine, drug...
2022-06-17 08:50 Lipum’s toxicology- and safety program of SOL-116 successfully completed
The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) has been carried out in collaboration with the contract...
2022-05-25 11:30 Lipum participates at Redeye Growth Day 2022
Redeye Growth Day takes place on June 2 in Stockholm and will be a combination of a digital platform and live presentations. Lipum is "In Focus"...
PreviousNext

Investor relations